Von Willebrand disease and coronary artery disease: A contemporary review

Journal of Invasive Cardiology

Volumn 18, Issue 4, 2006, Pages 178-182

  Ky, Bonnie ^a   Kasner, Margaret ^a   Carver, Joseph R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANTITHROMBIN; BLOOD CLOTTING FACTOR 8 CONCENTRATE; CLOPIDOGREL; DESMOPRESSIN; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; HIRULOG; RECOMBINANT BLOOD CLOTTING FACTOR 8; RISTOCETIN; SIMVASTATIN; THROMBIN INHIBITOR; TIROFIBAN; VON WILLEBRAND FACTOR;

AUTOSOMAL DOMINANT INHERITANCE; AUTOSOMAL RECESSIVE INHERITANCE; BLEEDING DISORDER; CORONARY ARTERY DISEASE; DISEASE CLASSIFICATION; HUMAN; NOTE; PREVALENCE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VON WILLEBRAND DISEASE; CORONARY ARTERY ATHEROSCLEROSIS;

CORONARY ARTERIOSCLEROSIS; HUMANS; VON WILLEBRAND DISEASE;

EID: 33745081263     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Note

References (37)

1. Mannucci PM. Treatment of von Willebrand's disease. N Engl J Med 2004;351:683-694.
2. Sadler JE, Mannucci, PM, Berntorp E, et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000;84:160-174.
3. White GC, Sadler JE. von Willebrand disease: Clinical aspects of therapy. In: Hoffman R, Benz JE, Shattil SJ, et al (eds). Hematology: Basic Principles and Practice, 4th edition. Philadelphia: Elsevier, Inc., 2005: pp. 2121-2131.
4. Mannucci PM. How I treat patients with von Willebrand disease. Blood 2001;97:1915-1919.
5. James PR, De Belder AJ, Kenny MW. Successful percutaneous transluminal coronary angioplasty for acute myocardial infarction in von Willebrand's disease. Haemophilia 2002;8:826-827.
6. Macdonald J, Srinivasan M, More R. Percutaneous coronary intervention in a patient with von Willebrand's disease presenting with an acute coronary syndrome. J Invasive Cardiol 2006;18:174-177.
7. Ginsburg D, Wagner DD. Structure, biology, and genetics of von Willebrand factor. In: Hoffman R, Benz JE, Shattil SJ, et al (eds). Hematology: Basic Principles and Practice, 4th edition. Philadelphia: Elsevier, Inc., 2005: pp 2111-2117.
8. Rand JH, Senzel L. Laboratory evaluation of hemostatic disorders. In: Hoffman R, Benz JE, Shattil SJ, et al (eds). Hematology: Basic Principles and Practice, 4th edition. Philadelphia: Elsevier, Inc., 2005: p. 2007.
9. Konkle, BA. von Willebrand's Disease. In: Young NS, Gerson SL, High KA (eds). Clinical Hematology. Philadelphia: Elsevier, Inc., 200: pp. 830-841.
10. Griggs TR, Reddick RL, Sultzer D, Brinkhous KM. Susceptibility to atherosclerosis in aortas and coronary arteries of swine with von Willebrand's disease. Am J Path 1981;102:137-145.
11. Federici AB, Mannucci PM, Fogato E, et al. Autopsy findings in three patients with von Willebrand disease type IIB and type III: Presence of atherosclerotic lesions without occlusive arterial thrombi. Thrombosis and Haemostasis 1993;70:758-761.
12. Archbold RA, Robinson NM, Schilling RJ. Radial artery access for coronary angiography and percutaneous coronary intervention. BMJ 2004;329:443-446.
13. Kiemeneij F, Laarman GJ, Odekerken D, et al. A randomized comparison of percutaneous transluminal coronary angioplasty by the radial, brachial, and femoral approaches: The access study. J Am Coll Cardiol 1997;29:1269-1275.
14. Cantor WJ, Puley G, Natarajan MK, et al. Radial versus femoral access for emergent percutaneous coronary intervention with adjunct glycoprotein IIb/IIIa inhibition in Acute Myocardial Infarction - the RADIAL-AMI Pilot Randomized Trial. Am Heart J 2005; 150:543-549.
15. Saito S, Tanaka S, Hiroe Y, et al. Comparative study on transradial approach versus transfemoral approach in primary stent implantation for patients with acute myocardial infarction: Results of the test for myocardial infarction by prospective unicenter randomization for access sites (TEMPURA) trial. Catheter Cardiovasc Interv 2003;59: 26-33.
16. Koreny M, Riedmuller E, Nikfardjam M, et al. Arterial puncture closing devices compared with standard manual compression after cardiac catheterization. Systematic review and meta-analysis. JAMA 2005;291:350-357.
17. Exaire JE, Tcheng JE, Kereiakes DJ, et al. Closure devices and vascular complications among percutaneous coronary intervention patients receiving enoxaparin, glycoprotein IIb/IIIa inhibitors and clopidogrel. Catheter Cardiovasc Interv 2005;64:369-372.
18. Virtanen R, Kauppila M, Itala M. Percutaneous coronary intervention with stenting in a patient with haemophilia A and an acute myocardial infarction following a single dose of desmopressin. Thromb Haemost 2004;92:1154-1156.
19. Federici AB. Management of von Willebrand disease with Factor VIII/von Willebrand factor concentrates: Results from current studies and surveys. Blood Coagul Fibrinolysis 2005; 16(Suppl 1): S17-S21.
20. Arjomand H, Aquilina P, McCormick D. Acute myocardial infarction in a patient with von Willebrand disease: Pathogenetic dilemmas and therapeutic challenges. J Invasive Cardiol 2002;14:615-618.
21. Fragasso G, Camba L, Pizzetti, et al. Successful thrombolysis for acute myocardial infarction in type I von Willebrand's disease. Am J of Hematol 1998;57:179-185.
22. Antman EM, Cohen M, Radley D, et al. Assessment of the treatment effect of enoxaparin for unstable angina/Non-Q-wave myocardial infarction TIMI 11B-essence meta-analysis. Circulation 1999;100:1602-1608.
23. Blazing MA, de Lemos JA, White HD, et al. Safety and efficacy of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin. JAMA 2004;292:55-64.
24. The SYNERGY Trial Investigators. Enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy. JAMA 2004;292:45-54.
25. Petersen JL, Mahaffey KW, Hasselblad V. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes. JAMA 2004;292:89-96.
26. Krolick MA. Successful percutaneous intervention in a patient with severe hemophilia A using bivalirudin as the sole procedural anticoagulant. Haemophilia 2005;11:415-417.
27. Arora UK, Dhir M, Cintron G, Strom, JA. Successful multi-vessel percutaneous coronary intervention with bivalirudin in a patient with severe hemophilia A: A case report and review of the literature. J Invasive Cardiol 2004;16:330-332.
28. Lincoff AM, Bittl JA, Harrington RA. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention. REPLACE-2 randomized trial. JAMA 2003; 289:853-856.
29. Maroo A, Lincoff AM. Bivalirudin in PCI: An overview of the REPLACE-2 Trial. Seminars in Thrombosis and Hemostasis 2004; 30:329-336.
30. Aguirre FV, Gill JB. Increasing Benefit, Reducing Risk: Focusing on hemorrhagic complications in percutaneous coronary intervention. J Invasive Cardiol 2002;14:48B-54B.
31. Tcheng JE. Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: Bleeding, reversal, thrombocytopenia, and retreatment. Am Heart J 2000;139:S38-S45.
32. Satler LF. Bleeding complications with PCI. Catheter Cardiovasc Interv 2005;64:373-374.
33. Lopez LM. Clinical challenges of bleeding in percutaneous coronary intervention. Am J Health-Syst Pharm 2003; 60:S8-S14.
34. Sadler JE. von Willebrand Disease Type 1: A diagnosis in search of a disease. Blood 2003;101:2089-2093.
35. Sadler JE. New Concepts in von Willebrand disease. Annu Rev Med 2005;56:173-191.
36. Lavi S, Gruberg L, Kapeliovich M, et al. The impact of GP IIb/IIIa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction patients. J Invasive Cardiol 2005;17:296-299.
37. Kereiakes DJ, Montalescott G, Antman EM, et al. Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention: An expert consensus. Am Heart J 2002;144:615-624.